Anaplastic lymphoma kinase
From Proteopedia
| Line 2: | Line 2: | ||
[[Image:2xp2.png|left|200px|thumb|Crystal Structure of human anaplastic lymphoma kinase complex with anti-cancer drug, [[2xp2]]]] | [[Image:2xp2.png|left|200px|thumb|Crystal Structure of human anaplastic lymphoma kinase complex with anti-cancer drug, [[2xp2]]]] | ||
{{STRUCTURE_2xp2| PDB=2xp2 | SIZE=350| SCENE= |right|CAPTION= Human anaplastic lymphoma kinase complex with anti-cancer drug, [[2xp2]] }} | {{STRUCTURE_2xp2| PDB=2xp2 | SIZE=350| SCENE= |right|CAPTION= Human anaplastic lymphoma kinase complex with anti-cancer drug, [[2xp2]] }} | ||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
Revision as of 11:01, 8 May 2013
Anaplastic lymphoma kinase (ALK) which is a tyrosine kinase receptor is active in the development of the brain. Chromosomal translocation is observed in ca. 60% anaplastic large-cell lymphomas. The translocation creates a fusion gene composed of the 3’ end of ALK and the 5’ end of nucleophosmin gene. EML4/ALK fusion gene is observed in ca. 4% of non-small-cell lung cancer. Aberrant ALK activity is observed in other carcinomas as well. ALK is comprised by an extracellular domain, a single pass transmembrane domain and an intracellular kinase domain.
3D Structures of anaplastic lymphoma kinase
Updated on 08-May-2013
ALK kinase domain
2xb7, 2xba, 3aox – hALK + inhibitor – human
3l9p, 2yhv, 2yjr, 2yjs, 4fnw, 4fnx, 4anl – hALK (mutant)
3lcs – hALK (mutant) + staurosporine
4dce, 4fob, 4foc, 4fod, 4fny, 4fnz – hALK (mutant) + inhibitor
3lct – hALK (mutant) + ADP
2xp2 – hALK + anti-cancer drug
2yfx, 4anq, 4ans – hALK (mutant) + anti-cancer drug
